Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of murine erythroleukemia cells (MELC). Commitment, the irreversible initiation of the program of terminal-cell differentiation, is first detected in HMBA-sensitive DS19-SC9 MELC in culture after 10 to 12 h of exposure to HMBA. Vincristine (VC)-resistant MELC derived from the DS19-SC9 MELC line display increased sensitivity to HMBA and become committed with little or no latent period. In the present study, we showed that the MELC line Rl, which is resistant to HMBA-mediated differentiation, became sensitive to inducer if selected for a low level of VC resistance (<10 ng of VC per ml). Murine erythroleukemia cells (MELC) cultured with hexamethylene bisacetamide (HMBA) (21) are induced to terminal-cell division and hemoglobin accumulation (5) . Commitment is defined as acquisition of the irreversible capacity to express this differentiated phenotype despite removal of the inducer (5, 9) . In the parental MELC line, DS19-SC9, committed cells are first detected after 10 to 12 h of continuous culture with HMBA (5). HMBA-induced differentiation can be inhibited by tumor promoters, such as phorbol-12-myristate-13-acetate (TPA), and by the glucocorticoid dexamethasone (DEX) (2, 14, 24, 26) . Variants of MELC, such as Rl, have been selected for resistance to induction by HMBA (13) . The blocking of differentiation of Rl cells (13) and the sites of inhibition imposed by TPA and DEX (24, 26) occur within the precommitment or latent period. HMBAmediated MELC terminal differentiation is a multistep process (2, 6) involving protein kinase C(PKC)-mediated events (16) , modulation in the expression of a number of nuclear proto-oncogenes (including c-myb, c-myc, c-fos, and p53), and expression of genes for differentiated characteristics (14, 20, 22) .
Recently, we described a MELC line (V3.17) derived from DS19-SC9 that is resistant to inhibition of cell growth by vincristine (VC) (15) . These VC-resistant cells display an accelerated HMBA-mediated commitment characterized by little or no latent period, and they respond to lower concentrations of HMBA than the parental VC-sensitive MELC does. VC-resistant cells are also relatively resistant to TPA and DEX inhibition of HMBA-induced differentiation (15) .
In the present paper, we report the characteristics of cell lines derived from HMBA-resistant Rl cells which were selected for low levels of resistance to VC (<10 ng/ml). We provide evidence that VC-resistant Rl (Rl [VCR] 
MATERIALS AND METHODS
Cell lines and materials. DS19-SC9 is a cloned cell line derived from 745A, which was a gift from Charlotte Friend (6) . DS19-SC9 cells are induced to differentiate by HMBA and other agents (5, 9, 14, 21, 24) . TPA and DEX inhibit HMBA-induced differentiation of this MELC line (24, 26) . Rl is a cloned cell line of HMBA-resistant cells derived from DS19-SC9 MELC (13 taining 10% FCS at a density of 106 cells per ml; [3H] vinblastine (specific activity, 20 Ci/mmol) was added at a final concentration of 100 nM. Each determination was done in triplicate. A zero-time sample was obtained by immediate centrifugation of a portion of the cell suspension. Remaining cells were incubated at 37°C for 60 min and then pelleted and washed four times in ice-cold phosphate-buffered saline, pH 7.4. The cell pellet was dissolved by suspension in 0.2 ml of 0.5 N NaOH and incubated for 30 min (37°C). Radioactivity in the pellet was determined with a scintillation counter.
Determination of P-glycoprotein expression. A plasma membrane-enriched subcellular fraction was prepared from cells by a method modified from that of Peterson et al. (19) . Protein concentration was determined by the method of Lowry et al. (12) . Proteins in the membrane fraction were resolved by electrophoresis on 7.5% sodium dodecyl sulfatepolyacrylamide gel. Samples were not boiled before being loaded on the gels, to avoid loss of signal and changes in mobility (7) . Electrotransfer to nitrocellulose (0.45-,um pore size; Schleicher & Schuell, Inc., Keene, N.H.) was performed by the method of Burnette (1) . Blots were blocked overnight in 10% dry milk powder in Tris-saline (10 (24, 26) . We examined the effects of TPA and DEX on Rl[VCR]a cells in culture with HMBA. Growth, commitment, and differentiation (benzidine reactivity) of these cells were determined in the absence and presence of HMBA, with and without 10 ng of TPA per ml or 4 mM DEX ( Table 2 ). The growth of Rl[VCR]a cells in TPA or in TPA with HMBA was less suppressed than was the growth of DS19-SC9 cells under the same conditions. HMBA-induced commitment and benzidine reactivity of Rl[VCR]a cells were also less inhibited by TPA than those of DS19-SC9 cells (Table 2) . Rl[VCR]a cells were also somewhat less sensitive to DEX-mediated inhibition of differentiation than were DS19-SC9 cells, but the effect was not as pronounced as for resistance to TPA ( Table 2) .
Effect of inhibition of protein synthesis on commitment. It has been shown elsewhere (11) that induction of differentiation of MELC is transiently delayed by the inhibition of (25) . To determine whether verapamil could reverse the VC resistance of Rl[VCR]a cells and whether the reestablishment of VC sensitivity affected the response to HMBA, verapamil was added to cultures of Rl[VCR]a cells without and with HMBA or VC. Verapamil (3 ,ug/ml) had little or no effect on the rate of growth of Rl[VCR]a cells, but there was marked inhibition of Rl[VCR]a cell growth when these cells were exposed to both verapamil and VC together (Fig. 4A) . Exposure of Rl[VCR]a cells to verapamil and HMBA for as long as 18 h followed by the addition of 5 ng of VC per ml resulted in marked cell growth inhibition (Fig. 4B, curve 2 ). This suggests that verapamil can effectively suppress resistance of Rl[VCR]a cells for at least 18 h but that it has no effect on the accelerated kinetics of HMBA-mediated commitment of these MELC (Fig. 5) . Verapamil had no effect on the growth or commitment of DS19-SC9 or Rl cells (data not shown).
P-glycoprotein levels in Rl[VCR]a cells. The overexpression of a 140-kDa plasma membrane P-glycoprotein is associated with resistance to a number of cytotoxic agents, including VC, in cells expressing the so-called multidrug resistance phenotype (1, 8) . Rl[VCR]a cells do not overexpress the 140-kDa P-glycoprotein; the level of this protein is similar to that in the parental Rl cells (Fig. 6) . The levels of P-glycoprotein in both Rl and R1[VCR] cells may be slightly higher than that in DS19-SC9 cells, but they are distinctly lower than that in cell line V3.17(200), deliberately made highly VC resistant and clearly overexpressing the P-glycoprotein. (21) . MELC line Rl, derived from DS19-SC9, is resistant to HMBA-mediated differentiation (14) . Other MELC lines, selected for resistance to low concentrations of VC, display increased sensitivity to HMBA and are induced with little or no latent period (15) .
In (17) . However, the fraction contributed by PKC, differs between these cell lines. In general, MELC variants which are relatively resistant to induction are also relatively low in PKCP activity, while those with an accelerated response display higher PKC, activity (17) . The level of PKCa is fairly constant among the MELC tested. The level of PKC, in Rl[VCR]a cells is 4-fold that in Rl cells and about 2.5-fold that in DS19-SC9 cells (17) . A role for PKC activity during induction is further supported by the observation that depletion of PKC activity by exposure to TPA inhibits HMBA-mediated induction (16) . Even VC-resistant MELC, which are relatively resistant to inhibition of differentiation by TPA, can be depleted of PKC and inhibited with respect to differentiation if they are preincubated with TPA for about 6 h (17). On the basis of these observations, one can speculate that VC resistance is associated with elevated levels of PKCB activity and that this, in turn, may account for increased sensitivity to HMBA. One effect of HMBA during induction appears to involve translocation and activation of PKC at the plasma membrane (unpublished observation). The phosphorylation target of this PKC activity is unknown, but it may include the protein that is constitutively expressed in VC-resistant MELC or other proteins, such as members of the family of cell cycle-regulating proteins (4, 18) .
Another implication of the present findings is that clinically acquired resistance to differentiation inducers might be overcome by exposure to a cytotoxic agent, i.e., VC. This has possible implications for the design and implementation of trials of differentiation inducers in the treatment of cancer.
